Despite huge effort and remarkable medical advances, a large number of cancers remain stubbornly difficult to treat.
Oncology is one of the most complex areas of medicine and the future for many patients is bleak.
Every year, more than three million people in the European region are diagnosed with cancer and around two million die from the disease.1 The need for new therapies is urgent. In 2006, Astellas made a commitment to join the fight against cancer, channelling our expertise in developing first-in-class and best-in-class treatments to help meet the challenges faced by patients and their doctors. Since then, we have developed strong, specialist research capabilities and established collaborations with key organisations at the forefront of cancer research.
Through intense focus on the most promising investigational therapies and technologies, Astellas now offers a blossoming cancer drugs portfolio with a rich pipeline. In the coming years, we plan to launch new treatments for a range of malignancies, including prostate, breast, lung and bladder cancers.
Prostate cancer is the fifth most common cancer worldwide.2 Each year, 380,000 men across Europe find out that they have the disease and nearly 100,000 die from it.2 Treatment options when the condition advances are limited. Astellas is focusing on meeting this area of significant unmet need.
Find out more about prostate cancer at www.everymonthmatters.org
1. International Agency for Research on Cancer. GLOBOCAN 2008 Fast Stats WHO European Region. Available at http://globocan.iarc.fr/factsheet.asp. Last accessed 12 July 2013.
2. International Agency for Research on Cancer. GLOBOCAN 2008 Cancer Factsheet. Prostate Cancer Incidence, Mortality and Prevalence Worldwide in 2008 Summary. Available at http://globocan.iarc.fr/factsheet.asp. Last accessed 12 July 2013.
Learn more about our therapy areas:
Innovative therapies in preventing organ rejection after transplantation
World-leading approach in R&D to satisfy unmet patient needs in urological conditions
Our commitment is to developing first-in-class and best-in-class therapies
Addressing the complex challenges of serious fungal and bacterial infections
Pioneering treatments that effectively manage chronic pain